Novartis based on their current interest in Retts.
From Rett Syndrone Association of Australia:
"Novartis, a multinational biotechnology company, issued a statement in August 2020 to confirm full commitment to their gene therapy program for Rett Syndrome. This was followed by a press release from the company in March 2021 which reported recent results of gene therapy to treat patients with spinal muscular atrophy (SMA). These results are of enormous interest to those of us who are related in some way to girls with Rett Syndrome and have important ramifications".
Kens
Novartis based on their current interest in Retts.From Rett...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.17 |
Change
0.070(0.35%) |
Mkt cap ! $2.578B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.53 | $20.14 | $4.102M | 202.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 249 | $20.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.31 | 790 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |